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Renin inhibition in portal hypertension: Novel indication beyond
cardiovascular diseases?Aliskiren {2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methyl-
propyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-
(3-methoxypropoxy) phenyl]-octanamide hemifumarate},
a direct renin inhibitor, is recognized for its efficacy in
lowering systemic blood pressure.1 The vasodilatory effect of
aliskiren can be related to the upregulation of endothelial nitric
oxide synthase (NOS) expression by enhanced NOS mRNA
stability, as well as by post-transcriptional modification.2
In liver cirrhosis, the formation of regeneration nodules and
fibrotic bands in response to acute and chronic liver injuries
increase intrahepatic vascular resistance. Enhanced intra-
hepatic vascular tone also is associated with the phenomenon.
As a result, portal venous blood flow is hindered from effi-
ciently entering the liver. To divert the stagnant portal blood
flow, an array of portosystemic collateral vasculature gradually
develops. At the same time, the peripheral and splanchnic
vasodilatation leads to a reduced total peripheral vascular
resistance, increased splanchnic blood flow and portal blood
flow, systemic arterial hypotension, and compensatory tachy-
cardia along with increased cardiac output. This is the so-
called hyperdynamic circulatory state. Moreover, the reduced
total vascular resistance elicits an inadequate intravascular
volume, which triggers the activation of the renin-angiotensin-
aldosterone axis. Excessive sodium and water retention
subsequently can induce edema, ascites formation, hepatic
hydrothorax, and even hepatorenal syndrome.3 Throughout the
entire process, an uneven distribution of NOS expression and
NO synthesis has been noticed. NO, an endothelium-derived
potent vasodilatory substance, is a major contributor to
splanchnic and systemic vasodilatation, which leads to the
hyperdynamic circulatory syndrome in portal hypertension.4
Meanwhile, a functional deficit or decreased NO synthesis in
the intrahepatic microcirculation is also noted. Intrahepatic
vasorelaxation in response to receptor-dependent and -inde-
pendent endothelial NOS agonists, such as acetylcholine and
calcium-ionophore A23187, is significantly reduced.5 Endo-
thelial NOS activity is also found to be decreased in experi-
mental liver cirrhosis.6,7 It has also been reported that
a markedly enhanced intrahepatic vasoconstrictile response to
angiotensin II was found in cirrhotic rats.8 On the other hand,
NO also participates in vascular responsiveness in portosys-
temic collateral vascular bed. Acute NOS inhibition increases1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.08.022vascular tone and suppresses acetylcholine-induced dilatations
of portosystemic collaterals in portal hypertensive rats.9 The
long-term blockade of NO synthesis further increases porto-
systemic collateral resistance and alleviates portal-systemic
shunting.9 Additionally, NO may be involved in the develop-
ment and dilatation of collaterals. It has been suggested that
the process of portosystemic collateralization involves both
neoangiogenesis and opening of preexisting venous chan-
nels.10 For both events, NO is of crucial importance.
Since liver cirrhosis and portal hypertension are often
accompanied by renin-angiotensin-aldosterone axis activation,
the potential effect of renin inhibition deserves further clari-
fication. To address the real contribution of aliskiren in this
disease, its influences on different vascular bed are to be
concerned. In the current study, Hsieh et al11 revealed that
aliskiren reduced portal pressure in cirrhotic rats, which is
attributed to the amelioration of the angiotensin II-induced
intrahepatic vasoconstriction. Furthermore, the intrahepatic
vasodilatory response to acetylcholine is improved in cirrhotic
rats treated with aliskiren. This sophisticated work reveals that
low-dose aliskiren treatment (20 mg/kg/day) for 2 days
reduced portal pressure and intrahepatic resistance, whereas
systemic blood pressure was not significantly decreased. This
is quite noteworthy since excessive blood pressure reduction
could be harmful in cirrhotic patients with hyperdynamic
circulation with systemic hypotension. In a recent survey,
Chang et al found that aliskiren decreased portal pressure in
PVL rats12 as well as in cirrhotic rats.13 Aliskiren significantly
decreased SMA resistance and increased SMA and left adrenal
vein (the most prominent intra-abdominal portosystemic
collateral vessel in rodents) eNOS mRNA expression. In
addition, using an in situ portosystemic collateral vascular
perfusion model, preincubation of aliskiren attenuated the
collateral vasoconstrictive effects of AVP.12 Apart from the
well-known systemic arterial blood pressure lowering effect,
indication of a portal hypotensive effect of aliskiren is
encouraging. Portal pressure is determined by portal venous
inflow, intrahepatic vascular resistance and portosystemic
collateral vascular resistance. Taking the results of current and
recent investigations into consideration, it can be inferred that
aliskiren reduces portal pressure via intrahepatic resistance
and portosystemic collateral vascular resistance reduction.hinese Medical Association. All rights reserved.
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viation of fibrosis. Aliskiren ameliorates renal inflammation and
fibrosis induced by unilateral ureteral obstruction inmice.14 The
activation of the renin-angiotensin-aldosterone axis, especially
angiotensin II, increases transforming growth factor-b (TGF-b)
anda-SMAexpression in kidney (TGF-b is a key factor involved
in the progression of interstitial fibrosis elicited by renal injury).
It is also worth noting that in animal models with nonalcoholic
steatohepatitis, angiotensin II type 1 receptor blocker inhibits
activation of hepatic stellate cells, oxidative stress, expression of
TGF-b, expression of collagen genes, and liver fibrosis.15 It
remains unclear as to whether direct renin inhibition also exerts
antifibrotic effect and further investigation is necessary.
In conclusion, the latest animal studies demonstrate that
aliskiren exerts its portal hypotensive effect via reducing
intrahepatic and portosystemic collateral vascular resistance,
which has not been proved in the past. Nevertheless, caution
should be exercised when extrapolating the results of animal
experiments and their associated data into clinical practice.
Further study is essential to address the efficacy of aliskiren
and its safety in a clinical setting.
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